The Latest Breaking News from Lupus

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193  in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Three patients have undergone CAR T-cell therapy, which genetically alters their immune system to protect their organs

MYSURU

From stress to sunlight to hormones, here are five common factors that can contribute to a flare-up of Lupus symptoms.

A UK CHAIRTY is urging the public to join efforts to raise awareness of an incurable autoimmune disease as World Lupus Day is marked.

Wells Fargo is reiterating its Overweight rating after Kezar Life Sciences Inc's (NASDAQ:KZR) zeto (KZR-616) Phase 2 trial in dermatomyositis/polymyositis failed to top placebo on the trial's primary endpoint of mean total improvement score (TIS). The analysts had viewed the program as a free call option for shares at these levels and argued that there…

Lupus is a long-term condition that causes joint pain and skin rashes and has no cure.

The autoimmune disease lupus had ruined my life until I landed an interview at the Southbank Centre. After years of trying to fit in I’d found my tribe – and a way to get better

Get inspiration from innovative, interesting examples of JavaScript in action.